NCT04477057View on ClinicalTrials.gov

PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 21, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2021

Conditions
Solid Tumor
Interventions
DRUG

HS-10241

HS-10241 is a tablet in the form of 100 mg, oral, once daily.

Trial Locations (1)

100021

RECRUITING

Shanghai Chest Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

NCT04477057 - PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter